The PPARγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism

The PPARγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism

Recent evidence suggests that PPAR&#947; agonists may promote anti-tumor immunity. We show that immunogenic PDV cutaneous squamous cell carcinoma (CSCC) tumors are rejected when injected intradermally at a low cell number (1 &#215; 10<sup>6</sup>) into immune competent syngeneic...

Full description

Bibliographic Details
Main Authors: Raymond L. Konger, Ethel Derr-Yellin, Nurmukambed Ermatov, Lu Ren, Ravi P. Sahu
Format: Article
Language:English
Published: MDPI AG 2019-06-01
Series:Molecules
Subjects:
peroxisome proliferator activated receptor gamma
rosiglitazone
T-cells
myeloid cells
anti-tumor immunity
Online Access:https://www.mdpi.com/1420-3049/24/11/2192

Internet

https://www.mdpi.com/1420-3049/24/11/2192

Similar Items